Drug Profile
Research programme: Alzheimer's disease prophylactics - Modgene
Alternative Names: imatinib para-diaminomethylbenzene trihydrochlorideLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator ModGene Pharma
- Class Neuroprotectants
- Mechanism of Action Amyloid beta-protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease(Prevention) in USA
- 19 Jul 2017 Research programme: Alzheimer's disease therapeutics - Modgene is available for licensing as of 19 Jul 2017. www.modgenepharmallc.com
- 19 Jul 2017 Modgene has patent protection for Alzheimer's disease therapeutics (Prevention) in USA